1. Hedinger, C, Dillwyn Williams, E, Sobin, L 1989. The WHO histological classification of thyroid tumors. A commentary on the second edition. Cancer 63:908-911

2.Namba, H, Matsuo, K, Fagin, J 1990 Clonal composition of benign and malignant human thyroid tumors. J Clin In 86:.

3.. Parma, J, Duprez, L, Van Sande, J, et al. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651

4.. Tonacchera, M, Chiovato, L, Pinchera, A, et al. 1998 Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 83:492-8

5. Coclet, J, Foureau, F, Ketelbant, P, Galand, P, Dumont, J 1989. Cell population kinetics in dog and human adult thyroid. Clinical Endocrinol 31:655-665

6. Viglietto, G, Chiappetta, G, Martinez-Tello, F J, et al. 1995 RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11:1207-10

7. Hamburger, J I 1980; Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 50:1089-1093

8. Silverstein, G, Burke, G, Cogan, R 1967. The natural history of the auto-nomous hyperfunctioning thyroid nodule. Ann Intern Med 67:539

9. Evered, D, Clark, F, Peterson, V 1974. Thyroid function in euthyroid subjects with autonomous thyroid nodules. Clin Endocrinol 3:149

10. Horst, W, Rosler, H, Schneider, C, Labhart, A 1967. 306 cases of toxic adenoma. Clinical aspects; findings in radioiodine diagnostics; radiochromatography and histology; results of 131I and surgical treatment. J Nucl Med 8:515

11.Parma, J, Duprez, L, Van Sande, J, et al. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651

12.Suarez, H, du Villard, J, Caillou, B, Schlumberger, M, Parmentier, C, Monier, M 1991. Gsp mutations in human thyroid tumors. Oncogene 6:677-679

13. see 10

13a. DeGroot, L 1970. Lack of iodide trapping in "cold" thyroid nodules. Acta Endocrinol Panam 1:27

14. Field, J, Larsen, P, Yamashita, K, Mashiter, K, Dekke, A 1973. Demonstration of iodide transport defect but normal iodide organification in nonfunctioning nodules of human thyroid glands. J Clin Invest 52:2404

15. Fragu, P, Nataf, B 1977. Human thyroid peroxidase activity in benign and malign thyroid disorders. J Clin Endocrinol Metab 45:1089

16. Demeester-Mirkine, N, Van Sande, J, Corvilain, H, Dumont, J 1975. Benign thyroid nodule with normal iodide trap and defective organification. J Clin Endocrinol Metab 41:1169

17. Burke, G, Szabo, M 1972. Dissociation of in vivo and in vitro "autonomy" in hyperfunctioning thyroid nodules. J Clin Endocrinol Metab 35:199

18. Sande Van, J, Mockel, J, Boeynaems, J, Dor, P, Andry, G, Dumont, J 1980. Regulation of cyclic nucleotide and prostaglandin formation in normal human thyroid tissue and in autonomous nodules. J Clin Endocrinol Metab 50:776

19. Smanik, P, Ryu, K-Y, Thel, K, Mazzaferri, E, Jhiang, S 1997. Expression; exon-intron organization; and chromosome mapping of the human sodium iodide symporter. Endocrinology 138:3555-8

20.Arturi, F, Russo, D, Schlumberger, M, et al. 1998. Iodine symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83:2493-96

21. Thomas, C J, Buckwalter, J, Staab, E, Kerr, C 1976. Evaluation of dominant thyroid masses. Ann Surg 183:464

22. Sipple, J H 1984 Multiple endocrine neoplasia type 2 syndromes: historical perspectives. Henry Ford Hosp Med J 32:219-21

23.Schimke, R, Hartmann, W, Prout, T, Rimoin, D 1968. Syndrome of bilateral pheochromocytoma; medullary thyroid carcinoma; and multiple neuromas. N Engl J Med 279:1

24.Sapira, J, Altman, M, Vandyk, K, Shapiro, A 1965. Bilateral adrenal pheo-chromocytoma and medullary thyroid carcinoma. N Engl J Med 273:140

25. Duffy, B J, Fitzgerald, P 1950. Cancer of the thyroid in children. A report of twenty-eight cases. J Clin Endocrinol 10:1296

26. Clark, D 1955. Association of irradiation with cancer of the thyroid in children and adolescents. JAMA 159:1007

27. Modan, B, Ron, E, Werner, A 1977. Thyroid cancer following scalp irradiation. Therapeutic Radiology 123:741

28 DeGroot, L, Frohman, L, Kaplan, E, Refetoff, S e 1977. Radiation-Associated Thyroid Carcinoma. New York Grune & Stratton:539 pages

29. Refetoff, S, Harrison, J, Karanfilski, B, Kaplan, E, DeGroot, L, Bekerman, C 1975. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N Engl J Med 292:171

30 DeGroot, L, Paloyan, E 1973. Thyroid carcinoma and radiation. A Chicago endemic. JAMA 225:487

31. Sokal, J 1959. The problem of malignancy in nodular goiter -- recapitulation and a challenge. JAMA 170:61

32. Veith, F, Brooks, J, Grigsby, W, Selenkow, H 1964. The nodular thyroid gland and cancer. N Engl J Med 270:431

32.1 Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E, Alexander EK. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7.

33. Hoffman, G, Thompson, N, Heffron, C 1972. The solitary thyroid nodule. Arch Surg 105:379

34. Pacini, F, Fontanelli, M, Fugazzola, L, et al. 1994. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosisof unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Mertab 78:826-9

35. Rieu, M, Lame, M, Richard, A, et al. 1995. Prevalence of sporadic medullary thyroid carcinoma. the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) 42:453-7

36. Niccoli, P, Wion-Barbot, N, Caron, P, et al. 1997. Interest of routine measurement of serum calcitonin. Study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 82:338-341

37. Gagel, R 1997. The goitrous patient with an elevated serum calcitonin -- what to do? J Clin Endocrinol Metab 82:335

38. Hamlin, E, Vickery, A 1956. Needle biopsy of the thyroid gland. N Engl J Med 254:742

39. Walfish, P, Hazani, E, Strawbridge, H, Miskin, M, Rosen, B 1977. Combined ultrasound and needle aspiration cytology in the assessment and management of hypofunctioning thyroid nodule. Ann Intern Med 87:270

40. Gershengorn, M, McClung, M, Chu, W, Hanson, T, Weintraub, B, Robbins, J 1977. Fine-needle aspiration cytology in the preoperative diagnosis of thyroid nodules. Ann Intern Med 87:265

41.Baloch, Z, Sack, M, Livolsi, V, Gupta, P 1998. Fine-needle aspiration of thyroid. an institutional experience. Thyroid 8:565-9

42. Benvenga, S, Bartolone, L, Squadrito, S, Trimarchi, F 1997. Thyroid hormone autoantibodies elicited by diagnostic fine needle biopsy. J Clin Endocrinol Metab 82:4217-4223

43 Wilems, J-S, Lowhagen, T 1981. Fine needle aspiration cytology in thyroid disease. . Clin Endocrinol Metab 2:247

44 Gharib, H, Goellner, J, Johnson, D 1993. Fine needle aspiration cytology of the thyroid. A 12-year experience with 11;000 biopsies. Clin Lab Med 13:699-709

45. Pacini, F, Fugazzola, L, Lippi, F, et al. 1992 Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses. a clue to the diagnosis of metastatic thyroid cancer. J Clin Endocrinol Metab 74:1401-4

46. Chow, L S, Gharib, H, Goellner, J R, van Heerden, J A 2001 Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. Thyroid 11:1147-51

47. Khurana, K, Richards, V, Chopra, P, Izquierdo, R, Rubens, D, Mesonero, C 1998. The role of ultrasonography-guided fine-needle aspiration biopsy in the management of nonpalpable and palpable thyroid nodules. Thyroid 8:511

48. Erdogan, M, Kamel, N, Aras, D, Akdogan, A, Baskal, N, Erdogan, G 1998. Value of reaspirations in benign nodular thyroid disease. Thyroid 8:1087

49. Bieche, I, Ruffet, E, Zweibaum, A, Vilde, F, Lidereau, R, Franc, B 1997. MUC1 Mucin gene; transcripts; and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7:725

50 Brousset, P, Chaouche, N, Leprat, F, et al. 1997. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 82:4214-4216

51 Khoo, M L, Beasley, N J, Ezzat, S, Freeman, J L, Asa, S L 2002 Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814-8

51a.  Maruta, J; Hashimoto, H; Yamashita, H; Yamashita, H; Noguchi, S.               Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma. Arch Surg               139          83-88       2004.

52 Clark, O, Okerlund, M, Cavalieri, R, Greenspan, F 1979. Diagnosis and treatment of thyroid; parathyroid; and thyroglossal duct cysts. J Clin Endocrinol Metab 48:983

53. Marcocci, C, Vitti, P, Cetani, F, Catalano, F, Concetti, R, Pinchera, A 1991. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 72:209-13

54. Kendall, L, Condon, R 1969. Prediction of malignancy in solitary thyroid nodules. Lancet 1:1071

55. Miller, J, Hamburger, J 1965.. The thyroid scintigram. 1. The hot nodule. Radiology 84:66

56. Attie, J 1960. The use of radioactive iodine in the evaluation of thyroid nodules. Surgery 47:611

57. Dische, S 1964. The radioisotope scan applied to the detection of carcinoma in thyroid swellings. Cancer 17:473

58. Fujimoto, Y, Oka, A, Nagataki, S 1972. Occurrence of papillary carcinoma in hyperfunctioning thyroid nodule. Report of a case. Endocrinol Jpn 19:371

59. Scott, M, Crawford, J 1976. Solitary thyroid nodules in childhood. Is the incidence of thyroid carcinoma declining? Pediatrics 58:521

60.Messaris, G, Evangelou, G, Tountas, C 1973. Incidence of carcinoma in cold nodules of the thyroid gland. Surgery 74:447

61. Van den Bruel, A, Maes, A, De Potter, T, et al. 2002 Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87:1517-20

62. Hakama, M Berlin; Springer-Verlag Different world thyroid cancer rates; in Hedinger CE (ed). Thyroid Cancer. International Union Against Cancer Monograph Series:Vol 12.

63. Young, J J, Percy, C, Asire, A e 1082 pages Surveillance; Epidemiology; and End Results. Incidence and Mortality Data; 1973-77. National Cancer Institute Monograph 57 NIH Publication No. 81:2330

64. Goldstein, R, Hart, I 1983. Follow-up of solitary autonomous thyroid nodules treated with 131I. New Engl J Med 309:1473

65. Gorman, C, Robertson, J 1978. Radiation dose in the selection of 131I or surgical treatment for toxic thyroid adenoma. Ann Intern Med 89:85

66. Paracchi, A, Ferrari, C, Livraghi, T, et al. 1992. Percutaneous intranodular ethanol injection. A new treatment for autonomous thyroid adenoma. J Endocrinol Invest 15:353-362

67. Lippi, F, Ferrari, C, Manetti, L, et al. 1996. Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection. results of an Italian multicenter study. The Multicenter Study Group. J Clin Endocrinol Metab 81:3261-3264

68. Monzani, F, Caraccio, N, Goletti, O, et al. S54-8 Treatment of hyperfunctioning thyroid nodules with percutaneous ethanol injection. Eight years' experience. Exp Clin Endocrinol Diabetes 106: Suppl 4

69. Hamburger, J I 1980; Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 50:1089-1093

70. McCowen, K, Reed, J, BL., F 1980. The role of thyroid therapy in patients with thyroid cysts. Amer J Med 68:853

71. Treece, G, Georgitis, W, Hofeldt, F 1983 Resolution of recurrent thyroid cysts with tetracycline instillation. Arch Int Med 143: 2285.

72. Monzani, F, Lippi, F, Goletti, O, et al. 1994. Percutaneous aspiration and ethanol sclero-therapy for thyroid cysts. J Clin Endocrinol Metab 78:800-802

73. Zingrillo, M, Torlontano, M, Ghiggi, M, et al. 1996. Percutaneous ethanol injection of large thyroid cystic nodules. Thyroid 6:403-8

74.Del Prete, S, Caraglia, M, Russo, D, et al. 2002 Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid 12:815-21

75. see 70

76. Papini, E, Bacci, V, Panunzi, C, et al. 1993. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol 38:507-513

77. Burch, H 1995. Evaluation and management of the solid thyroid nodule. Endocrinol Metab Clin N Am 24:663-710

78. Mainini, E, Martinelli, I, Morandi, G, Villa, S, Stefani, I, Mazzi, C 1995. Levothyroxine suppressive therapy for solitary thyroid nodule. J Endocrinol Invest 18:796-799

79. Cooper, D 1995. Clinical review 66. Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab 80:331-334

80. Castro, M R, Caraballo, P J, Morris, J C 2002 Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 87:4154-9

81 Zelmanovits, F, Genro, S, Gross, J 1998. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 83:3881-3885

82. Herms, A, Huysmans, D 1998. Treatment of benign nodular thyroid disease. N Engl J Med 312:601-4

83. Larosa, G, Ippolito, A, Luppo, L, et al. 1996. Cold thyroid nodule reduction with l-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab; 81:4385-7

83.a. Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials Otolaryngol Head Neck Surg. 2005 Sep;133(3):391-6

84. Wemeau, J L, Caron, P, Schvartz, C, et al. 2002 Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 87:4928-34

85 see 77

86 Morita, T, Tamai, H, Ohshima, A, et al. 1989. Changes in serum thyroid hormone; thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. J Clin Endocrinol Metab 69:227

87 Woolner, L, Beahrs, O, Black, B, McConahey, W, Keating, F J vol 12 Long term survival rates. in Hedinger Chr E (ed). Thyroid Cancer. International Union Against Cancer: Monograph Series

88. Fogelfeld, L, Wiviott, M, Shore-Freedman, E, et al. 1989. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med 320:835-840

89. Bennedbaek, F, Hegedus, L 1999. Percutaneous ethanol injection therapy in benign solitary solid cold thyroid nodules. A randomized trial comparing one injection with three injections. Thyroid 9:225-233

90. Khurana, K, Labrador, E, Izquierdo, R, Mesonero, C, Pisharodi, L 1999. The role of fine-needle aspiration biopsy in the management of thyroid nodules in children; adolescents; and young adults. A multi-institutional study. Thyroid 9:383

91.Tan, G, Gharib, H 1997. Thyroid incidentalomas. management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226-31

92. Franceschi, S, Boyle, P, Maissonneuve, P, et al. 1993. The epidemiology of thyroid carcinoma. Critical Reviews in Oncogenesis 4:25

93. Parkin, D, Muir, C, Whelan, S, Gao, Y, Fenlay, J, Powell, J Vol. 6 Cancer incidence in five continents. IARC Scientific Publication 120 International Agency for Research on Cancer: Lyon

94 Goodman, M, Yoshizawa, C, Kolonel, L 1988. Descriptive epidemiology of thyroid cancer in Hawaii. Cancer 61:1272

95. Spitz, M, Sider, J, Katz, R, Pollack, E, Newell, G 1988. Ethnic patterns of thyroid cancer incidence in the United States; 1973-1981. Int J Cancer 42:549

96. Mortensen, J, Woolner, L, Bennett, W 1955. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 15:1270

97. Silverberg, S, Vidone, R 1966. Metastatic tumors in the thyroid. Pac Med & Surg 74:175

98. Hundahl, S A, Fleming, I D, Fremgen, A M, Menck, H R 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83:2638-48

99. Wahner, H, Cuello, C, Correa, P, Uribe, L, Gaitan, E 1966. Thyroid carcinoma in an endemic goiter area; Cali; Colombia. Am J Med 40:58

100. Belfiore, La Rosa, G, La Porta, G, et al. 1992. Cancer risk in patients with cold thyroid nodules. relevance of iodine intake; sex; age; and multinodularity. Am J Med 93:363

101. Namba, H, Matsuo, K, Fagin, J 1990 Clonal composition of benign and malignant human thyroid tumors. J Clin In 86:.

102. Coclet, J, Foureau, F, Ketelbant, P, Galand, P, Dumont, J 1989. Cell population kinetics in dog and human adult thyroid. Clinical Endocrinol 31:655-665

103. Curran, P, DeGroot, L 1991. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocrine Rev 12:135-150

104. Namba, H, Gutman, R, Matsuo, K, Alvarez, A, Fagin, J 1990 H-Ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 71: .

105. Namba, H, Rubin, S, Fagin, J 1990. Point mutations of Ras oncogenes are an early event in thyroid tumorigenesis. Molecul Endocrinol 4:1474

106. Karga, H, Lee, J-K, Vickery, A, Thor, A, Gaz, R, Jameson, J 1991. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832

106a. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90.

106b Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2007 Dec 5

107. Santoro, M, Carlomagno, F, Hay, I, et al. 1992. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517-1522

108. Jhiang, S, Sagartz, J, Tong, Q, et al. 1996. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375-378

108a.  Nikiforova, MN; Kimura, ET; Gandhi, M; Biddinger, PW; Knauf, JA; Basolo, F; Zhu, Z; Giannini, R; Salvatore, G; Fusco, A; Santoro, M; Fagin, JA; Nikiforov, YE.          BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.              J Clin Endocrinol Metab           88            5399-5404               2003.

109 Kroff, T, Sarraf, P, Pecciarini, L, et al. 2000. PAX8-PPAR(1 fusion oncogene in human thyroid carcinoma. Science 289:1357-1360

109a.  Powell, JG; Allard, BL; Sahin, M; Wang, X-L; Wang, X; Hay, ID; Hiddinga, HJ; Deshpande, SS; Kroll, TG; Grebe, SKG; Eberhardt, NL; McIver, B.   The PAX8/PPAR( fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPAR( inhibition.           Oncogene               2003.

110. Marques, A R, Espadinha, C, Catarino, A L, et al. 2002 Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-52

110.1Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn II GW, Tallini G, Kroll TG, Nikiforov YE.  RAS point mutations and PAX8-PPARg rearrangement in thyroid tumors:  evidence for distinct molecular pathways in thyroid follicular carcinoma.  J Clin Endocrinol Metab 88:2318-2326, 2003.

111. Vivaldi, A, Pacini, F, Martini, F, et al. 2003 Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. J Clin Endocrinol Metab 88:892-9

112. Puzianowska-Kuznicka, M, Krystyniak, A, Madej, A, Cheng, S Y, Nauman, J 2002 Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-8

112a.  Takano, T; Miyauchi, A; Yoshida, H; Nakata, Y; Kuma, K; Amino, N.           Expression of TR(1 mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma.    J Clin Endocrinol Metab           88            3447-3449               2003.

113.Liu, R T, Huang, C C, You, H L, et al. 2002 Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21:4830-7

114. Parma, J, Duprez, L, Van Sande, J, et al. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651

115. Suarez, H, du Villard, J, Caillou, B, Schlumberger, M, Parmentier, C, Monier, M 1991. Gsp mutations in human thyroid tumors. Oncogene 6:677-679

116. Matsuo, K, Friedman, E, Gejman, P, Fagin, J 1993. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors. Structural studies of the TSH-R and the -subunit of GS in human thyroid neoplasms. J Clin Endocrinol Metab 76:1446-1451

117. Shi, Y, Zou, M, Farid, N 1993. Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis. Clinical Endocrinol 39:269-274

118 Fagin, J, Matsuo, K, Karmakar, A, Chen, D, Tang, S-H, Koeffler, H 1993. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184

119 Wada, N, Duh, Q Y, Miura, D, Brunaud, L, Wong, M G, Clark, O H 2002 Chromosomal aberrations by comparative genomic hybridization in hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 87:4595-601

120. Larsson, C, Skogseid, B, Oberg, K, Nakamura, Y, Nordenskjold, M 1988. Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma. Nature 332:85-87

121. Quadro, L, Panariello, L, Salvatore, D, et al. 1994. Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 79:590-594

122. Marsh, D, Learoyd, D, Robinson, B 1995. Medullary thyroid carcinoma. Recent advances and management update. Thyroid 5:407

123. Wohllk, N, Cote, G, Bugalho, M, et al. 1996. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745

124. Loh, K C 1997 Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 7:107-13.

125. Fagin, J 1997. Familial nonmedullary thyroid carcinoma - The case for genetic susceptibility. J Clin Endocrinol Metab 82:342-344

126.no entry

127. no entry

128. Lloyd, K, Dennis, M 1963. Cowden's disease. A possible new symptom complex with multiple system involvement. Annals Int Med 58:136

129.see 134a

130.see 132

131.Camiel, M, Mule, J, Alexander, L, Benninghoff, D 1968. Association of thyroid carcinoma with Gardner's syndrome in siblings. N Engl J Med 278:1056

132.Parkin, J 1981. Familial multiple glomus tumors and pheochromocytomas. Ann Otol 90:.60

132a. Hemminki K, Eng C, Chen B  J FAMILIAL RISKS FOR NON-MEDULLARY THYROID CANCER Clin Endocrinol Metab. 2005 Jul 19;.

133. Stratakis, C, Courcoutsakis, N, Abati, A, et al. 1997. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation; myxomas; endocrine overactivity; and schwannomas (Carney Complex). J Clin Endocrinol Metab 82:2037-2043

134 Malchoff, C, Sarfarazi, M, Tendler, B, et al. 2000. Papillary thyroid carcinoma associated with papillary renal neoplasia. genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85:1758-1764

134a. Malchoff, C D, Malchoff, D M 2002 The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 87:2455-9

135. Wollman, S 1963. Production and properties of transplantable tumors of the thyroid gland in the Fischer rat. Recent Prog Hormone Research 19:579

136 Frantz, V, Kligerman, M, Harland, W, Phillips, M, Quimby, E 1957. A comparison of the carcinogenic effect of internal and external irradiation on the thyroid gland of the male Long- Evans rat. Endocrinology 61:574

137 Doniach, I 1953. The effect of radioactive iodine alone and in combination with nethylthiouracil upon tumor production in the rat's thyroid gland. Br J Cancer 7:181

138.to be entered

139.to be entered

140.Maloof, F, Dobyns, B, Vickery, A 1952. The effects of various doses of radioactive iodine on the function and structure of the thyroid of the rat. Endocrinology 50:612

141.Dobyns, B, Didtschenko, I 1961. Nuclear changes in thyroidal epithelium following radiation from radioiodine. J Clin Endocrinol Metab 21:699

142. . Duffy, B J, Fitzgerald, P 1950. Cancer of the thyroid in children. A report of twenty-eight cases. J Clin Endocrinol 10:1296

143. Clark, D 1955. Association of irradiation with cancer of the thyroid in children and adolescents. JAMA 159:1007

144. Modan, B, Ron, E, Werner, A 1977. Thyroid cancer following scalp irradiation. Therapeutic Radiology 123:741

145 DeGroot, L, Frohman, L, Kaplan, E, Refetoff, S e 1977. Radiation-Associated Thyroid Carcinoma. New York Grune & Stratton:539 pages

146. Refetoff, S, Harrison, J, Karanfilski, B, Kaplan, E, DeGroot, L, Bekerman, C 1975. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N Engl J Med 292:171

147. DeGroot, L, Paloyan, E 1973. Thyroid carcinoma and radiation. A Chicago endemic. JAMA 225:487

.148.Pifer, J, Hempelmann, L, Dodge, H, Hodges, F 1968. Neoplasms in the Ann Arbor Series of thymus-irradiated children; a second survey. Am J Roent; Rad Ther & Nucl Med 103:13

149. Saenger, E, Silverman, F, Sterling, T, Turner, M 1960. Neoplasia following therapeutic irradiation for benign conditions in childhood. Radiology 74:.889

150 Beach, S, Dolphin, G 1962. A study of the relationship between X-ray dose delivered to the thyroids of children and the subsequent development of malignant tumors. Phys Med Biol 6:583

151. Winship, T, Rosvoll, R 1961. Thyroid carcinoma in childhood. Cancer 14:734

152.. Maxon, H, Thomas, S, Saenger, E, Buncher, C, Kereiakes, J 1977. Ionizing irradiation and the induction of clinically significant disease in the human thyroid gland. Am J Med 63:967

152a. Sadetzki S, Chetrit A, Lubina A, Stovall M, Novikov I. Risk of thyroid cancer after childhood exposure to ionizing radiation for tinea capitis.J Clin Endocrinol Metab. 2006 Dec;91(12):4798-804

153. see 147

154 see 144

154a.  Hollowell, JG; Staehling, NW; Flanders, WD; Hannon, WH; Gunter, EW; Spencer, CA; Braverman, LE.     Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).            J Clin Endocrinol Metab           87            489-499          2002.

155. see 152

156.Perkel, V, Gail, M, Lubin, J, et al. 1988. Radiation-induced thyroid neoplasms. Evidence for familial susceptibility factors. J Clin Endocrinol Metab 66:1316

157. Hanford, J, Quinby, E, Frantz, V 1962. Cancer arising many years after radiation therapy. JAMA 181:404

158. DeLawter, D, Winship, T 1963. Follow-up study of adults treated with Roentgen rays for thyroid disease. Cancer 16:1028

159 Parker, L, Belsky, J, Yamamoto, T, Kawamoto, S, Keehn, R 1974. Thyroid carcinoma after exposure to atomic radiation. Ann Intern Med 80:600

160.Hancock, S, Cox, R, McDougall, I 1991. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325:599

161.Pacini, F, Vorontsova, T, Demidchik, E, et al. 1997. Post-chernobyl thyroid carcinoma in Belarus children and adolescents. Comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 82:3563-3569

161a.Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A,Yamashita S, Williams D. Risk of thyroid cancer after exposure to 131I in childhood J Natl Cancer Inst. 2005 May 18;97(10):724-32.

162.see147

162.a
Lyon JL, Alder SC, Stone MB, Scholl A, Reading JC, Holubkov R, Sheng X, White GL Jr, Hegmann KT, Anspaugh L, Hoffman FO, Simon SL, Thomas B, Carroll R, Meikle AW. Thyroid Disease Associated With Exposure to the Nevada Nuclear Weapons Test Site Radiation: A Reevaluation Based on Corrected Dosimetry and Examination Data. Epidemiology. 2006 Nov;17(6):604-614

163.see 146

164. Favus, J, Schneider, A, Stachura, M, et al. 1976. Thyroid cancer occurring as a late consequence of head-and-neck irradiation. N Engl J Med 294:1019

165. Maxon, H, Thomas, S, Saenger, E, Buncher, C, Kereiakes, J 1977. Ionizing irradiation and the induction of clinically significant disease in the human thyroid gland. Am J Med 63:967

166.Spitalnik, P, Straus, F 1978. Patterns of human thyroid parenchymal reaction following low-dose childhood irradiation. Cancer 41:1098

167. Roudebush, C, Asteris, G, DeGroot, L 1978. Natural history of radiation-associated thyroid cancer. Arch Intern Med 138:1631

168. Rao, D, Frame, B, Miller, M, Kleerekoper, M, Block, M, Parfitt, A 1980. Hyperparathyroidism following head and neck irradiation. Arch Intern Med 140:205

169. Conard, R 1975. A twenty-year review of medical findings in a Marshallese population accidentally exposed to radioactive fallout. Published by Brookhaven National Laboratory (BNL No. 50424) Upton: New York

170. Vickery, A The Williams & Wilkins Co Thyroid alterations due to irradiation. The Thyroid International Academy of Pathology Monograph No 5: Baltimore

171 Cantolino, S, Schmickel, R, Ball, M, Cisar, C 1966. Persistent chromosomal aberrations following radioiodine therapy for thyrotoxicosis. N Engl J Med 275:739

172. Sheline, G, Lindsay, S, McCormack, K, Galante, M 1962. Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine. J Clin Endocrinol Metab 2: 8

173 Dobyns, B, Sheline, G, Workman, J, Tompkins, E, McConahey, W, Becker, D 1974. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism. A report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38:976

174 Holm, L-E, Dahlqvist, I, Israelsson, A, Lundell, G 1980. Malignant thyroid tumors after iodine 131-therapy. N Engl J Med 303:188

175 Holm, L-E, Eklund, G, Lundell, G 1980. Incidence of malignant thyroid tumors in humans after exposure to diagnostic doses of iodine-131. II. Estimation of thyroid gland size; thyroid radiation; and predicted versus observed number of malignant thyroid tumors. J Natl Cancer Inst 65:1221

176. Stanbury, J F g p 273 in Stanbury, JB; Wyngaarden, JB; Fredrickson, DS (eds). The Metabolic Basis of Inhterited Disease. New York: McGraw-Hill Book Co Inc

177. McGirr, E, Clement, W, Currie, A, Kennedy, J 1959. Impaired dehalogenase activity as a cause of goiter with malignant changes. Scott Med J 4:232

178. Elman, D 1958. Familial association of nerve deafness with nodular goiter and thyroid carcinoma. N Engl J Med 259:219

179. Medeiros-Neto, G, Oliveira, N 1970. Follicular adenocarcinoma of thyroid associated with congenital hyperplastic goiter. Acta Endocrinol Panam 1:73

180.Cooper, D, Axelrod, L, DeGroot, L, Vickery, A, Maloof, F 1981. Congenital goiter and the development of metastatic follicular carcinoma with evidence for a leak of nonhormonal iodide. Clinical; pathological; kinetic; and biochemical studies and a review of the literature. J Clin Endocrinol Metab 52:294

181. Sloan, L 1954. Of the origin; characteristics and behaviour of thyroid cancer. J Clin Endocrinol Metab 14:1309

182. Ellenbert, A, Goldman, L, Gordan, G, Lindsay, S 1962. Thyroid carcinoma in patients with hyperparathyroidism. Surgery 51:708

183. LiVolsi, V, Feind, C 1976. Parathyroid adenoma and nonmedullary thyroid carcinoma. Cancer 38:1391

184. Shapiro, S, Friedman, N, Perzik, S, Catz, B 1970. Incidence of thyroid carcinoma in Graves' disease. Cancer 26:1261

185. see 147

186. see 184

187. Belfiore, A, Garofalo, M, Giuffrida, D, et al. 1990. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 70:830

188. Pellegriti, G, Belfiore, A, Giuffrida, D, Lupo, L, Vigneri, R 1998. Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab 83:2805

189.Filetti, S, Belfiore, A, Amir, S, et al. 1988. The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. N Engl J Med 318:753

190.see DeGroot/Paloyan

191.Belfiore, A, Garofalo, M, Giuffrida, D, et al. 1990. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 70:830

192. Valenta, L, Lemarchand-Beraud, T, Nemec, J, Griessen, M, Bednar, J 1970. Metastatic thyroid carcinoma provoking hyperthyroidism; with elevated circulating thyrostimulators. Am J Med 48:72

193. Greenspan, F, Lowenstein, J, West, M, Okerlund, M 1972. Immunoreactive material to bovine TSH in plasma from patients with thyroid cancer. J Clin Endocrinol Metab 35:795

194.Greenspan, F, Lew, W, Okerlund, M, Lowenstein, J 1974. Falsely positive bovine TSH radioimmunoassay responses in sera from patients with thyroid cancer. J Clin Endocrinol Metab 38:1121

195.see 191

196.Mazzaferri, E 1990. Thyroid cancer and Graves' disease. J Clin Endocrinol Metab 70:826

197. Panza, N, Del Vecchio, L, Maio, M, et al. 1982. Strong association between an HLA- DR antigen and thyroid carcinoma. Tissue Antigens 20:155

198. Sampson, R, Woolner , L, Bahn, R, Kurland, L 1974. Occult thyroid carcinoma in Olmsted County; Minnesota. Prevalence at autopsy compared with that in Hiroshima and Nagasaki; Japan. Cancer 34:2072

199. Fukunaga, F, Yatani, R 1975. Geographic pathology of occult thyroid carcinomas. Cancer 36:1095

200 Hazard, J, Hawk, W, Crile, G J 1959. Medullary (solid) carcinoma of the thyroid. A clinicopathologic entity. J Clin Endocrinol Metab 19:152

201. Meier, D, Woolner, L, Beahrs, O, McConahey, W 1959. Parenchymal findings in thyroid carcinoma. Pathologic study of 256 cases. J Clin Endocrinol Metab 19:162

202. Lindsay, S, Dailey, M 1955. Malignant lymphoma of the thyroid gland and its relation to Hashimoto's disease. A clinical and pathologic study of 8 patients. J Clin Endocrinol Metab 15:1332

203. Rayfield, E, Nishiyama, R, Sisson, J 1971. Small cell tumors of the thyroid. A clinicopathologic study. Cancer 28:1023

204. Black, B, Kirk, T J, Woolner, L 1960. Multicentricity of papillary adenocarcinoma of the thyroid. Influence on treatment. J Clin Endocrinol Metab 20:130

205. Iida, F, Yonekura, M, Miyakawa, M 1969. Study of intraglandular dissemination of thyroid cancer. Cancer 24:764

206. Reed, R, Russin, D, Krementz, ET. 1966. Latent metastases from occult sclerosing carcinoma of the thyroid. JAMA 196:233

207. Hazard, J 1960. Small papillary carcinoma of the thyroid. Lab Invest 9:86
208.
208. Studer, H, Veraguth, P, Wyss, F 1961. Thyrotoxicosis due to a solitary hepatic metastasis of thyroid carcinoma. J Clin Endocrinol Metab 21:1334

209. Hunt, W, Crispell, K, McKee, J 1960. Functioning metastatic carcinoma of the thyroid producing clinical hyperthyroidism. Am J Med 28:995

210. Pochin, E 1960. Leukemia following radioiodine treatment of thyrotoxicosis. Br Med J 2:1545

211. Wyse, E, Hill, C, Ibanez, M, Clark, R 1969. Other malignant neoplasms associated with carcinoma of the thyroid. Thyroid carcinoma multiplex. Cancer 24:701

212. Shimaoka, K, Takeuchi, S, Pickren, J 1967. Carcinoma of thyroid associated with other primary malignant tumors. Cancer 20:1000

213. Halnan, K 1966. Influence of age and sex on incidence and prognosis of thyroid cancer. Cancer 19:1534

214. Russel, M, Gilbert, E, Jaeschke, W 1975. Prognostic features of thyroid cancer. A long term follow-up of 68 cases. Cancer 36:553

215. see 213

216. Rosvoll, R, Winship, T 1965. Thyroid carcinoma and pregnancy. Surg Gynecol Obstet 121:1039

217. Franssila, K 1975. Prognosis in thyroid carcinoma. Cancer 36:1138

218.Woolner, L, Lemmon, M, Beahrs, O, Black, B, Keating, F J 1960. Occult papillary carcinoma of the thyroid. Study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab 20:89-113

218a.  Passler, C; Prager, G; Scheuba, C; Niederle, BE; Kaserer, K; Zettinig, G; Niederle, B.               Follicular variant of papillary thyroid carcinoma:  a long-term follow-up.        Arch Surg               138          1362-1366               2003.

218b. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005 Jun 9;352(23):2406-12.

219.McConahey, W, Taylor, W, Gorman, C, Woolner, L Field Educational Italia Retrospective study of 820 patients treated for papillary carcinoma of the thyroid at the Mayo Clinic between 1946 and 1971. in Andreoli, M; Monaco, F; Robbins, J (eds). Advances in Thyroid Neoplasia: Rome

220. Franssila, K 1975. Prognosis in thyroid carcinoma. Cancer 36:1138

221. McDermott, W J, Morgan, W, Hamlin, E J, Cope, O 1954. Cancer of the thyroid. J Clin Endocrinol Metab 14:1336

222 Schlumberger, M, De Vathaire, F, Travagli, J, et al. 1987. Differentiated thyroid carcinoma in childhood. Long term follow-up of 72 patients. J Clin Endocrinol Metab 65:1088

223 Cady, B, Sedgwick, C, Meissner, W, Bookwalter, J, Romagosa, V, Werber, J 1976. Changing clinical; pathologic; therapeutic; and survival patterns of differentiated thyroid carcinoma. Ann Surg 184:541

224. Mazzaferri, E, Young, R 1981. Papillary thyroid carcinoma. A ten year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511

225. see 223

256 Harwood, J, Clark, O, Dunphy, J 1978. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 136:107

257. Mazzaferri, E, Young, R, Oertel, J, Kemmerer, W, Page, C 1977. Papillary thyroid carcinoma. The impact of therapy in 576 patients. Medicine 56:171

258. Terry, J, St John, S, Karkowski, F, al., e 1994. Tall cell papillary thyroid cancer. Incidence and prognosis. Am J Surg 168:459

259. Burman, K, Ringel, M, Wartofsky, L 1996. Unusual types of thyroid neoplasms. Endocrinol Metab Clinics North America 25:49-68

260.see 223

261.see 224

262.see 257

263.Frazell, E, Duffy, B 1954. Invasive papillary cancer of the thyroid. J Clin Endocrinol Metab 14:1362

264. Franssila, K 1975. Prognosis in thyroid carcinoma. Cancer 36:1138

265. Woolner, L, Lemmon, M, Beahrs, O, Black, B, Keating, F J 1960. Occult papillary carcinoma of the thyroid. Study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab 20:89

266. see 223

266a.  Chao, TC; Lin, JD; Chen, MF.        Insular carcinoma: Infrequent subtype of thyroid cancer with aggressive clinical course.   World J Surg           2004.

267. Young, R, Mazzaferri, E, Rahe, A, Dorfman, S 1980. Pure follicular thyroid carcinoma. Impact of therapy in 214 patients. J Nucl Med 21:733

268. Justin, E, Seabold, J, Robinson, R, Walker, W, Gurll, N, Hawe, D 1991. Insular carcinoma. A distinct thyroid carcinoma with associated Iodine-131 localization. J Nucl Med 32:1358-1363

269. McDermott, W J, Morgan, W, Hamlin, E J, Cope, O 1954. Cancer of the thyroid. J Clin Endocrinol Metab 14:1336

270. see 267

271. see269

272. see 223

273. see 267

274. Caplan, R, Abellera, R, Kisken, W 1994. Hurthle cell neoplasms of the thyroid gland. Reassessment of functional capacity. Thyroid 4:243

275. Cheung, C, Ezzat, S, Ramyar, L, Freeman, J, Asa, S 2000. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878-882

276 see 274

277. Harada, T, Ito, K, Shimaoka, K, Hosoda, Y, Yakumara, K 1977. Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma. Cancer 39:2588

278. Oppenheim, al., e 1983. Analplastic thyroid cancer presenting with hyperthyroidism. Amer J Med 75:702

279. Leedman, P, Sheridan, W, Downey, W, Fox, R, Martin, F 1990. Combination chemotherapy as single modality therapy for stage IE and IIE thyroid lymphoma. Med J Australia 152:40

280. Butler, J, Brady, L, Amendola, B 1990. Lymphoma of the thyroid. Report of five cases and review. Amer J Clin Oncol (CCT) 13:64

281. Souhami, L, Simpson, W, Carrothers, J 1980. Malignant lymphoma of the thyroid gland. Int J Radiat Oncol Biol Phys 6:1143

282. Kini, S, Miller, J, Hamburger, J 1981. Problems in the cytologic diagnosis of the "cold" thyroid nodule in patients with lymphocytic thyroiditis. Acta Cytol 25:506

283 Grimley, R, Oates, G 1980. The natural history of malignant thyroid lymphomas. Br J Surg 67:475

284. Siroto, D, Segal, R 1979. Primary lymphomas of the thyroid. JAMA 242:1743

284a
Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P. Second primary cancers in thyroid cancer patients: a multinational record linkage study J Clin Endocrinol Metab. 2006 May;91(5):1819-25

284bBrown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2008 Feb;93(2):504-15.

285.Cignarelli, M, Ambrosi, A, Marino, A, Lamacchia, O, Cincione, R, Neri, V 2002 Three cases of papillary carcinoma and three of adenoma in thyroglossal duct cysts: clinical-diagnostic comparison with benign thyroglossal duct cysts. J Endocrinol Invest 25:947-54

286. Hazard, J, Hawk, W, Crile, G J 1959. Medullary (solid) carcinoma of the thyroid. A clinicopathologic entity. J Clin Endocrinol Metab 19:152

287. see 22

288.see 23

289. Suarez, H, du Villard, J, Caillou, B, Schlumberger, M, Parmentier, C, Monier, M 1991. Gsp mutations in human thyroid tumors. Oncogene 6:677-679

290. Manning, P, Molnar, G, Black, M, Priestley, J, Woolner, L 1963. Pheochromocytoma; hyperparathyroidism; and thyroid carcinoma occurring coincidentally. N Engl J Med 268:68

291. Gorlin, R, Sedano, H, Vickers, R, Cervenka, J 1968. Multiple mucosal neuromas; pheochromocytoma; and medullary carcinoma of the thyroid -- a syndrome. Cancer 22:293

292. no entry

293. Gagel, R, Robinson, M, Donovan, D, Alford, B 1993. Medullary thyroid carcinoma. Recent progress. J Clin Endocrinol Metab 76:.809-814

294. Carney, J, Go, V, Sizemore, G, Hayles, A 1976. Alimentary-tract ganglioneuromatosis. N Engl J Med 295:1287

295 Noel, M, Delehaye, M-C, Segond, N, et al. 1991. Study of calcitonin and thyroglobulin gene expression in human mixed follicular and medullary thyroid carcinoma. Thyroid 1:249

296.DeGroot, L, Hoye, K, Refetoff, S, Van Herle, A, Asteris, G, Rochman, H 1977. Serum antigens and antibodies in the diagnosis of thyroid cancer. J Clin Endocrinol Metab 45:1220

297.Sobol, H, Narod, S N, Y, Boneu, A, et al. 1989. Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med 321:996-1001

298. Wolfe, H, Melvin, K, Cervi-Skinner, S, et al. 1973. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 289:437

299. Cox, T, Fagan, E, Hillyard, C, Allison, D, Chadwick, V 1979. Role of calcitonin in diarrhea associated with medullary carcinoma of the thyroid. Gut 20:629

300 Pacini, F, Basolo, F, Elisel, R, Fugazzola, L, Cola, A, Pinchera, A Amer J Clin Pathol. 95 300: 1991.

301- Kanamoto N, Akamizu T, Hosoda H, Hataya Y, Ariyasu H, Takaya K, Hosoda K, Saijo M, Moriyama K, Shimatsu A, Kojima M, Kangawa K, and Nakao K. Substantial production of Ghrelin by a human medullary thyroid carcinoma cell line. J Clin Endocrinol Metab 86:4984-4990, 2001

302. Cohen, S, Graham-Smith, D, MacIntyre, I, Walker, J 1973. Alcohol- stimulated calcitonin release in medullary carcinoma of the thyroid. Lancet 2:1172

303.Melvin, K, Tashjian, A 1968. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci USA 59:1216

304.see 200

305.. Larsson, C, Skogseid, B, Oberg, K, Nakamura, Y, Nordenskjold, M 1988. Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma. Nature 332:85-87

306 Quadro, L, Panariello, L, Salvatore, D, et al. 1994. Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 79:590-594

307. Marsh, D, Learoyd, D, Robinson, B 1995. Medullary thyroid carcinoma. Recent advances and management update. Thyroid 5:407

308. Wohllk, N, Cote, G, Bugalho, M, et al. 1996. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745

309. Melvin, K, Miller, H, Tashjian, A 1971. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 285:1115

310. Wahner, H, Cuello, C, Aljure, F 1968. Hormone-induced regression of medullary (solid) thyroid carcinoma. Am J Med 45:789

311. Barbot, N, Calmettes, C, Schuffenecker, I, et al. 1994. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin. Comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 78:114-120

312. see 311

313. Calmettes, C, Moukhtar, M, Milhaud, G 1977. Correlation between calcitonin and carcinoembryonic antigen levels in medullary carcinoma of the thyroid. Biomedicine 27:52

314. Hoefnagel, C, Delprat, C, Zanin, D, Van Der Schoot, J 1988. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159

315. see 311

316. Pacini, F, Ceccherini, I, Martino, E, et al. Abstract No. 182. Screening for ret gene mutations in multiple endocrine neoplasia (MEN) type 2 and in sporadic medullary thyroid carcinoma (MTC). clinical applications. Sixty-eighth annual meeting of the American Thyroid Association Chicago; IL: September 28-October 1; 1994

317. Sobol, H, Narod, S N, Y, Boneu, A, et al. 1989. Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med 321:996-1001

318. Lips, C, Landsvater, R, Hoppener, J, et al. 1994. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835

319. Black, H, Capen, C, Young, D 1973. Ultimobranchial thyroid neoplasms in bulls. Cancer 32:865

319a.
Machens, A; Niccoli-Sire, P; Hoegel, J; Frank-Raue, K; van Vroonhoven, TJ; Roeher, H-D; Wahl, RA; Lamesch, P; Raue, F; Conte-Devolx, B; Dralle, H.             Early malignant progression of hereditary medullary thyroid cancer.        N Engl J Med     349      1517-1525       2003.

320.Graze, K, Spiler, I, Tashijan, A J, et al. 1978. Natural history of familial medullary thyroid carcinoma. N Engl J Med 299:980

320.1 Scollo C, Baudin E, Travagli J-P, Caillou B, Bellon N, Leboulleux S, Schlumberger M.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.  J Clin Endocrinol Metab 88:2070-2075, 2003.

321. . Deftos, L, Stein, M 1980. Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50:967

322. Hellman, D, Kartchner, M, Van Antwerp, J, Salmon, S, Patton, D, O'Mara, R 1979. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48:451

323. Kim, S, Morimoto, S, Kawa, i Y, Koh, E, Onishi, T, Ogihara, T 1989. Circulating levels of calcitonin gene-related peptide in patients with medullary thyroid carcinoma. J Clin Chem Clin Biochem 27:423

324. Moley, J, Wells, S, Dilley, W, Tisell, L 1993. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114:1090-1095

325. Frank-Raue, K, Raue, F, Buhr, H, Baldauf, G, Lorenz, D, Ziegler, R 1992. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation. High sensitivity of selective venous catheterization. Thyroid 2:113

326. Simpson, W 1975. Radiotherapy in thyroid cancer. Can Med Assoc J 113:115

327. Brierley, J, Tsang, R, Simpson, W, Gospodarowicz, M, Sutcliffe, S, Panzarella, T 1996. Medullary thyroid cancer. Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-310

328. Fersht, N, Vini, L, A'Hern, R, Harmer, C 2001 The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 11:1161-8

329. Samaan, N, Schultz, P, Hickey, R Medullary thyroid carcinoma. Prognosis of familial versus nonfamilial disease and the role of radiotherapy.

330. Hoefnagel, C, Delprat, C, Zanin, D, Van Der Schoot, J 1988. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159

331 DeGroot, L 1970. Lack of iodide trapping in "cold" thyroid nodules. Acta Endocrinol Panam 1:27

332. Kim, B W, Daniels, G H, Harrison, B J, et al. 2003 Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 88:594-8

333. Huang, S A, Fish, S A, Dorfman, D M, et al. 2002 A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 87:4457-61

334. Abe, Y, Ichikawa, Y, Muraki, T, Ito, K, Momma, M 1981. Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors. Absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab 52:23

335.Carayon, P, Thomas-Morvan, C, Castanas, E, Tubiana, M 1980. Human thyroid cancer. Membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 51:915

336. 1. Burke, G, Szabo, M 1972. Dissociation of in vivo and in vitro "autonomy" in hyperfunctioning thyroid nodules. J Clin Endocrinol Metab 35:199

337. 1. Van Sande, J, Mockel, J, Boeynaems, J, Dor, P, Andry, G, Dumont, J 1980. Regulation of cyclic nucleotide and prostaglandin formation in normal human thyroid tissue and in autonomous nodules. J Clin Endocrinol Metab 50:776

337a. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma J Clin Endocrinol Metab. 2006 Jan;91(1):213-20.

337b.Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9

337.c Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V,Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. Clin Endocrinol Metab. 2005 Sep;90(9):5270-8

338. 1. Franklin, W, Mariotti, S, Kaplan, D, DeGroot, L 1982. Immunofluorescence localization of thyroglobulin in metastatic thyroid cancer. Cancer 50:939

339. Goudie, R, McCallum, H 1963. Loss of tissue-specific autoantigens in thyroid tumors. Lancet 1:348

340. Pontius, K, Hawk, W 1980. Loss of microsomal antigen in follicular and papillary carcinoma of the thyroid. An immunofluorescence and electron-microscope study. Am J Pathol 74:620

341. Meier, D, Woolner, L, Beahrs, O, McConahey, W 1959. Parenchymal findings in thyroid carcinoma. Pathologic study of 256 cases. J Clin Endocrinol Metab 19:162

342.to be entered

343. to be entered

344 DeGroot, L, Hoye, K, Refetoff, S, Van Herle, A, Asteris, G, Rochman, H 1977. Serum antigens and antibodies in the diagnosis of thyroid cancer. J Clin Endocrinol Metab 45:1220

345 Aoki, N, DeGroot, L 1979. Lymphocyte blastogenic response to human thyroglobulin in Graves' disease; Hashimoto;s thyroiditis; and metastatic thyroid cancer. Clin Exp Immunol 38:523

346. Amino, N, Pysher, T, Cohen, E, DeGroot, L 1975. Immunologic aspects of human thyroid cancer. Cancer 36:963

347. Mariotti, S, DeGroot, L, Scarborough, D, Medof, M 1979. Study of circulating immune complexes in thyroid diseases. Comparison of Raji cell radioimmunoassay and specific thyroglobulin-antithyroglobulin radioassay. J Clin Endocrinol Metab 49:679

348. Pacini, F, Mariotti, S, Formica, N, et al. 1988 Thyroid autoantibodies in thyroid cancer. Incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 119:373

349. Rubello, D, Casara, D, Girelli, M, Piccolo, M, Busnardo, B 1992. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer. a prospective study. J Nucl Med 33:1478

350. Rocklin, E, Gagel, R, Feldman, Z, Tashijan, A J 1977. Cellular immune responses in familial medullary thyroid carcinoma. N Engl J Med 296:835

351. Belfiore, A, Garofalo, M, Giuffrida, D, et al. 1990. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 70:830

352. Pellegriti, G, Belfiore, A, Giuffrida, D, Lupo, L, Vigneri, R 1998. Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab 83:2805

353.Filetti, S, Belfiore, A, Amir, S, et al. 1988. The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. N Engl J Med 318:753

354. Wu, P-C, Leslie, P, McLaren, K, Toft, A 1989. Diffuse sclerosing papillary carcinoma of thyroid. A wolf in sheep's clothing. Clin Endocrinol 31:535

355. Cignarelli, M, Triggiani, V, Ciampolillo, A, et al. 2001. High frequency of incidental diagnosis of extrathyroidal neoplastic diseases at the fine-needle aspiration biopsy of laterocervical lymph nodes in patients with thyroid nodules. Thyroid 11:65

356. Van Herle, A, Uller, R 1975. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J Clin Invest 56:272

356a. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007 Feb;92(2):450-5

357. Meighan, J, Dworkin, H 1969. Failure to detect 131I positive thyroid metastases with 99mTc. J Nucl Med 11:173

358. Fairweather, D, Bradwell, A, Watson-James, S, Dykes, P, Chandler, S, Hoffenberg, R 1983. Detection of thyroid tumors using radio-labelled thyroglobulin. Clin Endocrinol 18:563

359. O'Byrne, K, Hamilton, D, Robinson, I, al., e 1992. Imaging of medullary carcinoma of the thyroid using 111In-labelled anti-CEA monoclonal antibody fragments. Nucl Med Commun 13:142

360. Thomas, C, Pepper, F, Owen, J 1969. Differentiation of malignant from benign lesions of the thyroid gland using complementary scanning with 75Selenomethionine and radioiodide. Ann Surg 170:396

361 Yano, K, Morita, S, Furukawa, Y, al., e 1978. Diagnosis of malignant neoplasms with 201Ti chloride. Jpn J Nucl Med 15:989

362. to be added

363. Higashi, T, Ito, K, Nishikawa, Y, al., e 1988. Gallium-67 imaging in the evaluation of thyroid malignancy. Clin Nucl Med 13:792

364. Skowsky, W, Wilf, L 1991. 131Iodine metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid. South Med J 84:636

365.Lamberts, S, Reubi, J-C, Krenning, E 1993. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol 32:167

366.see 359

367. Wang, W, Larson, S, Fazzari, M, et al. 2000. Prognostic value of [18F]-Fluorodeoxy-glucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113

367.1 van Tol KM, Jager PL, Piers A, Pruim J, de Vries EGE, Dullaart RPF, Links TP.  Better yield of  18Fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.  Thyroid 12:381, 2002.

367a.  Chin, BB; Patel, P; Cohade, C; Ewertz, M; Wahl, R; Ladenson, P.               Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.  J Clin Endocrinol Metab           89            91-95       2004.

368. Ridder, R, Willeke, F, Lacroix, J, et al. Detection of thyroglobulin mRNA in peripheral blood of patients with thyroid cancer.

369a.  Elisei, R; Vivaldi, A; Agate, L; Molinaro, E; Nencetti, C; Grasso, L; Pinchera, A; Pacini, F.          Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.     J Clin Endocrinol Metab           89            29-32       2004.

369b.Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Brainard J, Gupta MK. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.J Clin Endocrinol Metab. 2007 Feb;92(2):468-75

370. Harmer, M Springer-Verlag Application of TNM classification rules to malignant tumors of the thyroid gland; in Hedinger CE (ed). Thyroid Cancer. UICC Monograph Series 12.64: Berlin

371.   Sobin LH, Wittekind Ch (eds) TNM Classification of Malignant Tumors, 6th Edition . Wiley-Liss, New YOrk, pp 52-56

371a. Tennvall J, Biorklund A, Moller T et al. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid Carcinoma? Cancer 57:1405, 1986

371b. Pasieka JL, Zedenius J, Azuer G et al; Addition of nuclear content to the AMES risk-group classification for papillary thyroid cancer: Surgery 112:1154, 1992.

371c. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma. Surgery 114: 1050, 1993.

372. Yano, K, Morita, S, Furukawa, Y, al., e 1978. Diagnosis of malignant neoplasms with 201Ti chloride. Jpn J Nucl Med 15:989

373. Van Herle, A, Uller, R 1975. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J Clin Invest 56:272

374. see 370

375. to be added

376. Buckwalter, J, Thomas, C 1972. Selection of surgical treatment for well differentiated thyroid carcinomas. Ann Surg 176:565

377. Tollefsen, H, Shah, J, Huvos, A 1972. Papillary carcinoma of the thyroid. Recurrence in the thyroid gland after initial surgical treatment. Am J Surg 124:468

378. Rickey, O, Howard, R 1967. Cancer of the thyroid. Am J Surg 112:637

379. to be added

380. Clark, R, Ibanez, M, White, E 1966. What constitutes an adequate operation for carcinoma of the thyroid? Arch Surg 92:23

381. Rustad, W, Lindsay, S, Dailey, M 1963. Comparison of the incidence of complications following total and subtotal thyroidectomy for thyroid carcinoma. Surg Gynecol Obstet 116:109

382. Thompson, N, Harness, J; 1970. Complications of total thyroidectomy for carcinoma. Surg Gynecol Obstet 131:861

383. Samaan, N, Schultz, P, Hickey, R, et al. 1992. The results of various modalities of treatment of well differentiated thyroid carcinoma. A retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720

384. Tollefson, H, DeCosse, J 1964. Papillary carcinoma of the thyroid. The case for radical neck dissection. Am J Surg 108:547

385. Crile, G J, Suhrer, J J, Hazard, J 1955. Results of conservative operations for malignant tumors of the thyroid. J Clin Endocrinol Metab 15:1422

386. Crile, G J 1971. Changing end results in patients with papillary carcinoma of the thyroid. Surg Gynecol Obstet 132:460

387.Glass, H, Waldron, G, Allen, H J, Brown, W 1960. A rational approach to the thyroid malignancy problem. Am Surg 26:81

388.see 385

389.see386

390. Cady, B, Sedgwick, C, Meissner, W, Bookwalter, J, Romagosa, V, Werber, J 1976. Changing clinical; pathologic; therapeutic; and survival patterns of differentiated thyroid carcinoma. Ann Surg 184:541

391. see 376.

392. see 376
393.
394. Shands, W, Gatling, R 1970. Cancer of the thyroid. Review of 109 cases. Ann Surg 171:735
395.
396. see 384
397.
398. to be entered
399.
400. see 378
401.
402. see 376
403.
404. see 380
405.
406. see 378
407.
400. Tollefsen, H, Shah, J, Huvos, A 1972. Papillary carcinoma of the thyroid. Recurrence in the thyroid gland after initial surgical treatment. Am J Surg 124:468

401. Rosvoll, R, Winship, T 1965. Thyroid carcinoma and pregnancy. Surg Gynecol Obstet 121:1039

402. Samaan, N, Schultz, P, Hickey, R, et al. 1992. The results of various modalities of treatment of well differentiated thyroid carcinoma. A retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720

403. Hay, I, Grant, C, Bergstralh, E, Thompson, G, van Heerden, J, Goellner, J 1998. Unilateral total lobectomy. Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 124:958-966

404. Rustad, W, Lindsay, S, Dailey, M 1963. Comparison of the incidence of complications following total and subtotal thyroidectomy for thyroid carcinoma. Surg Gynecol Obstet 116:109

405. Thompson, N, Harness, J; 1970. Complications of total thyroidectomy for carcinoma. Surg Gynecol Obstet 131:861

406. Mazzaferri, E, Young, R, Oertel, J, Kemmerer, W, Page, C 1977. Papillary thyroid carcinoma. The impact of therapy in 576 patients. Medicine 56:171

407. Tollefson, H, DeCosse, J 1964. Papillary carcinoma of the thyroid. The case for radical neck dissection. Am J Surg 108:547

408. see 407

409. Glass, H, Waldron, G, Allen, H J, Brown, W 1960. A rational approach to the thyroid malignancy problem. Am Surg 26:81

410. Hirabayashi, R, Lindsay, S 1961. Carcinoma of the thyroid gland--a statistical study of 390 patients. J Clin Endocrinol Metab 21:1596

411. Hay, I, Bergstralh, E, Goellner, J, Ebersold, J, Grant, C 1993. Predicting outcome in papillary thyroid carcinoma. development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057

412Meissner, W, Colcock, B, Achenback, H 1955. The pathologic evaluation of radical neck dissection for carcinoma of the thyroid gland. J Clin Endocrinol Metab 15:1432

413.see 411

414. Block, G, Wilson, S 1971. A modified neck dissection for carcinoma of the thyroid. Surg Clin North Am 51:139

415. Mustard, R 1970. Treatment of papillary carcinoma of the thyroid with emphasis on conservative neck dissection. Am J Surg 120:697

416. McGovern, J, Mannex, H J 1967. Thirty year experience with thyroid cancer. NY State J Med 67:2207

417. Exelby, P, Frazell, E 1969. Carcinoma of the thyroid in children. Surg Clin North Am 49:249

418. Werk, E, Vernon, B, Gonzalez, J, Ungaro, P, McCoy, R 1984. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 144:474

418a Triponez F, Poder L, Zarnegar R, Goldstein R, Roayaie K, Feldstein V, Lee J, Kebebew E, Duh QY, Clark OH. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease.J Clin Endocrinol Metab. 2006 Dec;91(12):4943-7

419. Klapp, C, Rosvoli, R, Winship, T 1967. Is destructive surgery ever necessary for treatment of thyroid cancer in children? Ann Surg 165:745

420. Wolf, G, Kohek, P, Geyer, E, et al. 1996. Intraoperative radiation therapy; endotracheal hyperthermia and IR-192-brachytherapy in patients with advanced thyroid cancer. Acta Medica Austriaca 23:76-79

421. Nishida, T, Nakao, K, Hamaji, M 1997. Differentiated thyroid carcinoma with airway invasion. Indication for tracheal resection based on the extent of cancer invasion. J Thorac Cardiovas Surg 114:84-92

422. Ozaki, O, Sugino, K, Mimura, T, Ito, K 1995. Surgery for patients with thyroid carcinoma invading the trachea. Circumferential sleeve resection followed by end-to-end anastomosis. Surgery 117:268-271

423. Sugenoya, A, Matsuo, K, Asanuma, K, et al. 1995. Management of tracheal wall resection for thyroid carcinoma by tracheocutaneous fenestration and delayed closure using auricular cartilage. Head & Neck 17:339-342

424. Schlumberger, M, Arcangioli, O, Piekarski, J, Tubiana, M, Parmentier, C 1988. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790-1794

425. Ruegemer, J, Hay, I, Bergstralh, E, Ryan, J, Offord, K, Gorman, C 1988. Distant metastases in differentiated thyroid carcinoma. A multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508

426. Exelby, P, Frazell, E 1969. Carcinoma of the thyroid in children. Surg Clin North Am 49:249

427. Klapp, C, Rosvoli, R, Winship, T 1967. Is destructive surgery ever necessary for treatment of thyroid cancer in children? Ann Surg 165:745

428. Liechty, R, Safaie-Shirazi, S, Soper, R 1972. Carcinoma of the thyroid in children. Surg Gynecol Obstet 134:595

429. Pacini, F, Gasperi, M, Fugazzola, L, et al. 1994. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 35:1418

430. McClellan, D, Francis, G 1996. Thyroid cancer in children; pregnant women; and patients with Graves' disease. Endocrinol Metab Clinics North America 25:27-48

431. Casara, D, Rubello, D, Saladini, G, et al. 1993. Pregnancy after therapeutic doses of iodine-131 in differentiated thyroid cancer. potential risks and recommendations. Eur J Nucl Med 20:192

432. Schlumberger, M, De Vathaire, F, Ceccarelli, C, et al. 1996. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606

433. Schlumberger, M, De Vathaire, F, Travagli, J, et al. 1987. Differentiated thyroid carcinoma in childhood. Long term follow-up of 72 patients. J Clin Endocrinol Metab 65:1088

433a. Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, Drake WM, Plowman PN, Besser GM, Chew SL, Grossman AB, Monson JP, Britton KE. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Nucl Med Commun. 2006 Feb;27(2):165-9.

434. Cady, B, Sedgwick, C, Meissner, W, Bookwalter, J, Romagosa, V, Werber, J 1976. Changing clinical; pathologic; therapeutic; and survival patterns of differentiated thyroid carcinoma. Ann Surg 184:541

435. Mazzaferri, E, Young, R, Oertel, J, Kemmerer, W, Page, C 1977. Papillary thyroid carcinoma. The impact of therapy in 576 patients. Medicine 56:171

436. Mazzaferri, E, Young, R 1981. Papillary thyroid carcinoma. A ten year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511

437.see 436

438. Samaan, N, Schultz, P, Hickey, R, et al. 1992. The results of various modalities of treatment of well differentiated thyroid carcinoma. A retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720

439. DeGroot, L, Reilly, M 1982. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 96:51

440. Roos, D e a 1999. Review of trials assessing low dose radioactive iodine ablation for thyroid remnants in patients with thyroid cancer. International J Rad Oncol Biol Physiol 44:493-495. 1.

440a. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, Filetti S, Trischitta V. Comparative Evaluation of Recombinant Human Thyrotropin-Stimulated Thyroglobulin Levels, 131I Whole-Body Scintigraphy, and Neck Ultrasonography in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine Therapy. J Clin Endocrinol Metab. 2006 Jan;91(1):60-3.

440b. Czepczynski R, Ziemnicka K, Baczyk M, Oleksa R, Ruchala M, Sowinski J. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Thyroid. 2005 Nov;15(11):1261-5.

440c. Nucl Med Commun. 2003 May;24(5):489-95. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA.

441. Wartofsky, L, Sherman, S, Gopal, J, Schlumberger, M, Hay, I 1998. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83:4195-4203

442. Caplan, R, Abellera, R, Kisken, W 1994. Hurthle cell neoplasms of the thyroid gland. Reassessment of functional capacity. Thyroid 4:243

423. Carcangiu, M, Bianchi, S, Savino, D, Voynick, I, Rosai, J 1991. Follicular Hurthle cell tumors of the thyroid gland. Cancer 68:1944-1953
424.
444. Pacini, F, Molinaro, E, Castagna, M G, et al. 2002 Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-8

445. Robbins, R J, Tuttle, R M, Sonenberg, M, et al. 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-9

445a. Kuijt WJ, Huang SA.; Children with Differentiated Thyroid Cancer Achieve Adequate Hyperthyrotropinemia within 14 Days of Levothyroxine Withdrawal. J Clin Endocrinol Metab. 2005 Aug 9

446. Guimaraes, V, DeGroot, L 1996. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 6:69-73

447. Schlumberger, M 1998. Papillary and follicular thyroid carcinoma. N Engl J Med 338:.297-306

448. Dow, K, Ferrell, B, Anello, C 1997. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7:613-619

449. Ramirez, L, Braverman, L, White, B, Emerson, C 1997. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 82:2836-2839

450. Meier, C, Braverman, L, Ebner, S, et al. 1994. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab; 78:188-96

451. Ladenson, P, Braverman, L, Mazzaferri, E, al., e 1997. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-95

452. Haugen, B, Pacini, F, Reiners, C, et al. 1999. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885

452.1 Driedger, AA; Kotowycz, N.    Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.      J Clin Endocrinol Metab 89    585-590     2004.

452a. Sorvillo, F; Mazziotti,G; Carbone, A; Piscopo, M; Rotondi, M; Cioffi, M; Musto, P; Biondi, B; Iorio, S; Amato, G; Carella, C.     Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue.    J Clin Endocrinol Metab 88    4818-4822   2003.

452b Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer. 2005 Mar;12(1):49-64.

453. Bachelot, A, Cailleux, A F, Klain, M, et al. 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12:707-11

454.Pacini, F, Capezzone, M, Elisei, R, Ceccarelli, C, Taddei, D, Pinchera, A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-501

455. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, and Pinchera A.    Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.   J Clin Endocrinol Metab  86:5686-5690, 2001
 
455a.
Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, Wolffenbuttel BH, Links TP. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 2008 Jan;158(1):77-83 : Eur J Endocrinol. 2008 Jan;158(1):77-83.

455b.Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008 Jan;93(1):76-81

456. Mazzaferri, E, Kloos, R 2002. Is diagnostic Iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498

457. Wartofsky, L 2002. Using baseline and recombinant human TSH-stimulated tg measurements to manage thyroid cancer without diagnostic 131I scanning. J Clin Endocrinol Metab 87:1486-1489

458.Wartofsky, L 2002 Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583-90

459a Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur J Endocrinol. 2005 Nov;153(5):651-9.

459b.David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC.  Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid. 2005 Mar;15(3):267-73. -

459c. Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP,Schlumberger M. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf). 2005 Mar;62(3):376-9.

459d. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourechi V. Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients. J Clin Endocrinol Metab. 2007 Jan;92(1):82-7.

460.see 457

461.see 454

462.Lippi, F, Capezzone, M, Angelini, F, et al. 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 144:5-11

463. Galloway, R, Smallridge, R 1996. Imaging in thyroid cancer. Endocrinol Metab Clinics North America 25:93-113

464. Park, H-M, Perkins, O, Edmondson, J, Schnute, R, Manatunga, A 1994. Influence of diagnostic radioiodines on the uptake of ablative dose of Iodine-131. Thyroid 4:49

464a. Lassmann,M Luster M, Hanscheid H, Reiners C. Impact of 1313-I diagnostic Activities on the Biokinetics of Thyroid Remnants. J Nucl Med 45: 619-625, 2004.

465. Morris, L F, Waxman, A D, Braunstein, G D 2001 The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 86:3507-11

465a. Nucl Med Commun. 2004 Aug;25(8):799-805. Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Haq MS, McCready RV, Harmer CL.)(J Nucl Med. 2003
Mar;44(3):451-6.

465b. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA.)

465.1. Cailleux, A, Baudin, E, Travagli, J, Ricard, M, Schlumberger, M 2000. Is diagnostic Iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178

465.2. Van Nostrand, D, Atkins, F, Yeganeh, F, Acio, E, Bursaw, R, Wartofsky, L 2002. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12:121-134

465.3. O'Connell, M, Flower, M, Hinton, P, Harmer, C, McCready, V 1993. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiotherapy-Oncology 28:16-26

465.31 Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006 Oct;47(10):1587-91.

465.4. Maxon, H, Thomas, S, Hertzberg, V, et al. 1983. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937

465.5. Koong, S-S, Reynolds, J, Movius, E, et al. 1999. Lithium as a potential adjuvant to 131I therapy of metastatic; well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912-916

465.6. Carcangiu, M, Bianchi, S, Savino, D, Voynick, I, Rosai, J 1991. Follicular Hurthle cell tumors of the thyroid gland. Cancer 68:1944-1953

465.7. Fatourechi, V, Hay, I, Mullan, B, et al. 2000. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cance